Paxman launches first neuropathy system to target chemo side effects
Paxman has launched its Paxman Neuropathy System in Europe, expanding beyond scalp cooling to try to reduce chemotherapy-induced peripheral neuropathy. The rollout comes with published clinical data showing the device was safe, well tolerated and linked to low rates of neuropathy in a multicenter study.
Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, can cause numbness, pain, tingling and loss of feeling in the hands and feet. - CIPN remains one of oncology’s biggest unmet needs because there is no established standard preventive therapy. - The condition can damage quality of life and force chemotherapy dose reductions, delays or treatment stoppage. - Paxman’s launch extends the company beyond scalp cooling and into another major treatment side effect.
What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System, a cryocompression device designed to help reduce the risk and severity of CIPN. - The launch was announced Nov. 5, 2026, from Huddersfield, West Yorkshire, United Kingdom. - The company is rolling out the system in the United Kingdom, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already underway in the United Kingdom.
The details: - The Paxman Neuropathy System uses cryocompression technology to address a side effect that affects millions of cancer patients worldwide each year. - CIPN can make routine tasks such as walking, writing, dressing and sleeping more difficult. - Symptoms can persist long after treatment ends. - Paxman has spent more than 25 years building its global leadership in scalp cooling, a position strengthened by the 2025 acquisition of Dignitana. - The new product marks Paxman’s first major expansion beyond scalp cooling. - The launch coincided with publication of prospective multicenter phase I/II data in JCO Oncology Advances. - The study evaluated the Paxman Neuropathy System in patients receiving taxane-based chemotherapy. - Researchers concluded the device was safe, well tolerated and associated with low rates of CIPN. - Among 146 evaluable patients, none developed severe neuropathy. - Patient-reported clinically significant sensory symptoms stayed low throughout follow-up. - The launch also aligned with a review in Therapeutic Advances in Medical Oncology on the causes, impact and prevention of CIPN. - The review highlighted cryotherapy and cryocompression as among the most promising emerging interventions.
Between the lines: - Paxman is positioning cryocompression as a practical prevention strategy for a side effect that can disrupt cancer care and everyday life. - The published clinical findings help support the commercial launch with early evidence, but the broader clinical case will depend on continuing studies. - The company is trying to turn expertise in scalp cooling into a wider oncology side-effect platform. - Richard Paxman OBE said the launch opens a new chapter for the company and reflects a broader mission to help patients manage treatment-related side effects.
What’s next: - Paxman plans to expand the system to additional European centers over the coming months. - Research is continuing through the randomized SWOG S2205 ICE COMPRESS study in the United States. - An additional ongoing clinical trial at Dana-Farber Cancer Institute is also evaluating the Paxman Neuropathy System. - More clinical and real-world data will determine how widely the system is adopted in oncology care.
The bottom line: - Paxman is moving beyond hair-loss management and into neuropathy prevention, backed by early clinical data and a broader push to reduce chemotherapy side effects.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Spain Consumer Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.